Daily close, T-120 (8/12/24) through T+5. Run-up high $175.24 on 9/9/24, low $126.4 on 11/27/24 (T-120 to T-1). FDA decision 1/27/25. Historical price action, not a forecast.
Positioning before the decision
On Jan 13, 2025, 14 days before the decision date, at-the-money options priced a move of ±4.1% through Jan 31, 2025 (the first listed expiry after the decision; ATM implied volatility 23%). The stock closed +1.5% at the first close across the decision and +2.5% five trading days on. A straddle priced weeks out covers ordinary movement plus the event, so this is the move the options market priced through that expiry, not the event-implied move alone. How this compares across 1,000+ decisions.
Decision facts
FDA decision date2025-01-27
DrugEnhertu - (DESTINY-Breast06)
IndicationHR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer
Was Enhertu - (DESTINY-Breast06) approved by the FDA?
Yes. The FDA approved the application for Enhertu - (DESTINY-Breast06) on January 27, 2025. The primary source is linked on this page.
What was Enhertu - (DESTINY-Breast06) under FDA review for?
The application covered HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer. The FDA approved the application on January 27, 2025.
How did AZN stock react to the FDA decision?
On the decision day AZN moved +0.7%. That is the recorded reaction to this specific event -- historical measurement, not a prediction, and not investment advice.